Serum leptin in obese patients with Laron syndrome before and during IGF-I treatment

Journal of Pediatric Endocrinology and Metabolism

Volumn 11, Issue 5, 1998, Pages 653-656

  Laron, Z ^a,c   Silbergeld, A ^a   Lilos, P ^a   Blum, F W F ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b LILLY DEUTSCHLAND GMBH   (Germany)

^c SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

IGF I treatment; Laron syndrome; Leptin; Obesity

Indexed keywords

FK 780; GROWTH HORMONE BINDING PROTEIN; LEPTIN; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INFANT; LARON SYNDROME; MALE; OBESITY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031784526     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.1998.11.5.653     Document Type: Article

References (26)

1. Laron Z. Prismatic cases: Laron syndrome (primary growth hormone resistance). From patient to laboratory to patient. J Clin Endocrinol Metab 1995; 80: 1526-1531.
2. Laron Z, Pertzelan A, Karp M, Kowadlo-Silbergeld A. Daughaday WH. Administration of growth hormone to patients with familial dwarfism with high plasma immunoreactive growth hormone. Measurement of sulfation factor, metabolic and linear growth responses. J Clin Endocrinol Metab 1971; 33: 332-342.
3. Godowski PJ, Leung DW, Meacham LR, Galgani JP, Hellmiss R, Keret R, Rotwein PS, Parks JS, Laron Z , Wood WI. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in 2 patients with Laron type dwarfism. Proc Natl Acad Sci USA 1989; 86: 8083-8087.
4. Amselem S, Duquesnoy P, Attree O, Novelli G, Bousnina S, Postel-Vinay MC, Goosens M, Laron dwarfism and mutations of the growth hormone receptor gene. New Engl J Med 1989; 321: 989-995.
5. Berg MA, Argente J, Chernausek S, Gracia R, Guevara-Aguirre J, Hopp M, Perez-Jurado L, Rosenbloom AL, Toledo SPA, Francke U. Diverse growth hormone receptor gene mutations in Laron syndrome. Am J Hum Genet 1993; 52: 998-1005.
6. Silbergeld A, Dastot F, Klinger B, Kanety H, Eshet R, Amselem S, Laron Z. Intronic mutation in the growth hormone (GH) receptor gene from a girl with Laron syndrome and extremely high serum GH binding protein: extended phenotypic study in a very large pedigree. J Pediatr Endocrinol Metab 1997; 10: 265-274.
7. Laron Z, Klinger B, Eshet R, Kaneti H, Karasik A, Silbergeld A. Laron syndrome due to a post-receptor defect: response to IGF-I treatment. Isr J Med Sci 1993; 29: 757-763.
8. Bauman G, Shaw MA, Winter RJ. Absence of plasma growth hormone-binding protein in Laron-type dwarfism. J Clin Endocrinol Metab 1987; 65: 814-816.
9. Daughaday WH, Trivedi B. Absence of serum growth hormone binding protein in patients with growth hormone receptor deficiency (Laron dwarfism). Proc Natl Acad Sci USA 1987; 84: 4636-4640.
10. Laron Z, Klinger B, Erster B, Silbergeld A. Serum GH binding protein activity identifies the heterozygous carriers for Laron-type dwarfism. Acta Endocrinol (Copenh) 1989; 121: 603-608.
11. Maheshwari HG, Clayton PE, Mughal Z, Price DA, Norman M. Laron type dwarfism: the GH-BP positive phenotype. Lessons from Laron syndrome 1966-1992. A model of GH and IGF-I action and interaction. Pediatr Adolesc Endocrinol 1993; 24: 160-166.
12. Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone. A new inborn error of metabolism? Isr J Med Sci 1966; 2: 152-155.
13. Laron, Z, Pertzelan A, Karp M. Pituitary dwarfism with high serum levels of growth hormone. Isr J Med Sci 1968; 4: 883-894.
14. Laron Z, Klinger B. Body fat in Laron syndrome patients: effect of insulin-like growth factor I treatment. HormRes 1993; 40: 16-22.
15. Laron Z, Klinger B. IGF-I treatment of adult patients with Laron syndrome: Preliminary results. Clin Endocrinol 1994; 41: 531-538.
16. Klinger B, Laron Z. Three year IGF-I treatment of children with Laron syndrome. J Pediatr Endocrinol Metab 1995; 8: 149-158.
17. Tritos NA, Mantzoros CS. Leptin: its role in obesity and beyond Diabetologia 1997; 40: 1371-1379.
18. Kiess W, Siebler T, Englaro P, Kratzch J, Deutscher J, Meyer K, Gallaher B, Blum WF. Leptin as a metabolic regulator during fetal and neonatal life and in childhood and adolescence. J Pediatr Endocrinol Metab 1998; 11: 483-496.
19. Blum WF, Englaro P, Hanitsch S, Juul A, Hertel NT, Muller J, Skakkebaek NE, Heiman ML, Birkett M, Attanasiko AM, Kiess W, Rascher W. Plasma leptin levels in healthy children and adolescence: dependence on BMI, body fat mass, gender, pubertal stage and testosterone. J Clin Endocrinol Metab 1997; 82: 2904-2910.
20. Silbergeld A, Litwin A, Bruchis S, Varsano I, Laron Z. Insulin-like growth factor I (IGF-I) in healthy children adolescents and adults as determined by a radio-immunoassay specific for the synthetic 53-70 peptide region. Clin Endocrinol 1986; 25: 67-74.
21. Blum WF, Kiess W, Rascher W. Leptin - The Voice of Adipose Tissue. Heidelberg-Leipzig: Johann Ambrosius Barth Verlag, 1997; pp 333.
22. Klein S, Coppack SW, Mohamed AV, Landi M. Adipose tissue leptin production and plasma leptin kinetics in humans. Diabetes 1996; 45: 984-987.
23. Laron Z, Avitzur Y, Klinger B. Insulin resistance in Laron syndrome (primary insulin-like growth factor-I [IGF-I] deficiency) and effect of IGF-I replacement therapy. J Pediatr Endocrinol Metab 1997; 10 (Suppl 1): 105-115.
24. Klinger B, Laron Z. Renal function in Laron syndrome patients treated by insulin-like growth factor-I, Pediatr Nephrol 1994; 8: 684-688.
25. Fisker S, Vahl N, Hansen TB, Jorgensen JOL, Hagen C, Orskov H, Christiansen JS. Serum leptin is increased in growth-hormone deficient adults: Relationship to body composition and effects of placebo-controlled growth hormone therapy for 1 year. Metabolism 1997; 46: 812-817.
26. Al-Shoumer KAS, Anyaoku V, Richmond W, Johnston DG. Elevated leptin concentrations in growth hormone-deficient hypopituitary adults. Clin Endocrinol 1997; 47: 153-159.